Eric L. Michelson, MD

• AstraZeneca LP
• Wilmington, DE
• Department of Medicine
• Division of Cardiology
• Jefferson Medical College
• Philadelphia, PA

Hepatitis E was not thought to play an important role in disease in Western countries prostate youtube discount rogaine 5 60 ml on-line, but is increasingly recognized as a common pathogen in those areas prostate cancer gleason score rogaine 5 60 ml purchase fast delivery. Changes in population behavior can also significantly influence changes in overall epidemiology prostate cancer 9 gleason purchase 60 ml rogaine 5 amex. Liver biopsy findings are not consistent with drug hepatotoxicity and in fact show decreases in hepatic inflammation man health zinc generic rogaine 5 60 ml online. Both didanosine and stavudine demonstrate increased risk of mitochondrial toxicity prostate cancer stage 4 60 ml rogaine 5 purchase free shipping, relative to other nucleoside/nucleotide analogs. Except for the immune-mediated injury processes, hepatocyte injury tends to be dose-dependent. Thus, high doses of ritonavir are intrinsically hepatotoxic, but boosting doses are generally safe. Liver Biopsy and Noninvasive Markers of Liver Disease Severity Accurate determination of the presence and degree of hepatic fibrosis is essential for prognostication and guiding treatment decisions in patients with chronic liver diseases. Liver biopsy, however, is invasive and carries a complication rate ranging from 1% to 5%, with the risk of mortality ranging from 1 in 1000 to 1 in 10,000. Models derived from routine tests are most ideal, if proven accurate, because they are both cost-effective and readily available. Nonroutine tests tend to represent more direct measures of collagen deposition or liver function and include tests of hepatic metabolic activity, extracellular matrix remodeling proteins, collagen synthesis and degradation products, and enzymes involved in matrix degradation. The Forns index should not be used in patients with genotype 3, however, due to varying serum cholesterol levels. Transient Elastography Elastography or elastometry is a noninvasive method of measuring the mean stiffness of hepatic tissue with hepatic rigidity considered a marker of fibrosis severity. The other tests were able to classify fibrosis well in only 37% to 61% of patients and with lower accuracies. This demonstrated that these tests were able to accurately determine degree of fibrosis in greater than 50% of the coinfected population. Used individually, it was determined that liver biopsy could be avoided in 22% of patients, and when used sequentially, this number increased to 30%. These patients should then have additional testing to exclude conditions associated with portal hypertension (varices and hepatocellular carcinoma). Granulomatous processes (infectious and nonspecific) may require tissue diagnosis and noninvasive measures may provide false readings in those patients. Contaminated drinking water and ingestion of contaminated seafood represent key sources of infection. The prevalence was greater among men compared with women; among non-Hispanics compared with Hispanics; and among patients aged 35 to 44 years compared with younger or older patients. However, treatment should generally be continued even after seroconversion as seroreversion and reactivation are possible. In the event of prior lamivudine exposure or resistance, tenofovir plus emtricitabine has been recommended. This rate is approximately 20% in 2 years for telbivudine and 29% in 5 years for adefovir. To date, no clinically significant resistant mutations have been demonstrated against tenofovir in vivo. The antiviral efficacy of tenofovir does not seem to be affected by prior lamivudine exposure and lamivudine resistance. Whereas generally well tolerated, tenofovir may be associated with renal tubular abnormalities, including Fanconi syndrome and overt renal failure. Within the gutassociated lymphocyte population, alterations in FoxP3+ regulatory T cell populations have been observed and correlated with liver inflammation. Third, there is accelerated hepatocyte apoptosis in coinfection, leading to more inflammation and fibrosis. In those that test negative, repeat testing is recommended yearly as long as patients have ongoing risks (high-risk sexual activity, illicit drug use). Data from several trials in coinfected patients show similar response rates and tolerability to monoinfected patients with interferon freeregimens. In certain individuals treatment could be deferred if there is no fibrosis, other contraindications to treatment, or concerns regarding adherence. Liver involvement has been reported to be up to 44% of patients at autopsy in certain studies. Whereas liver involvement is generally clinically silent, severe disease can occur in the setting of disseminated/systemic involvement. Ganciclovir and related antivirals, depending on disease severity, are the mainstay of treatment in immunocompromised patients, especially with diffuse disease. Though primarily a pulmonary process, up to one third may have associated hepatic involvement. Hepatic imaging may reveal low-attenuation lesions and biopsy shows patchy granular necrosis without significant inflammation. As the name implies, it is generally spread via exposure to cats through a bite or a scratch. These are associated with sinusoidal damage and development of aneurysmal dilation of the central vein. In contrast, patients with marked impairment of hepatic synthetic function with increases in direct conjugated bilirubin along with elevations of aminotransferases are at risk for liver-related mortality. Furthermore, in a randomized controlled trial that compared lopinavir therapy boosted with low-dose ritonavir and nelfinavir, only 4. Hypersensitivity reactions have been reported for trimethoprim-sulfamethoxazole, abacavir, nevirapine, atazanavir, enfuvirtide, fosamprenavir, and maraviroc and are often related to genetically mediated processes of drug metabolism. Significant decreases in mitochondrial function can result in decreased oxidative phosphorylation leading to increased lactate production. Clinically, mitochondrial toxicity is manifested by nausea, vomiting, and abdominal pain, which can progress to severe acidosis. In those with these features or in those with Grade 3 or 4 toxicity (>5 times increase in liver enzymes or >3. Patients frequently present with abdominal pain, hepatomegaly, and increased alkaline phosphatase levels. Exclude other possible causes of acute hepatitis Consider discontinuation of antiretroviral therapy If suspicion of mitochondrial toxicity or acute hypersensitivity reaction. Furthermore, these agents have become more tolerable and drug-drug interactions have been reduced, though not eliminated. However, post hoc analysis reveals that poor outcomes are associated with a limited number of controllable factors including donor age, single versus multiple organ transplant, and center experience. However, progression of anal intraepithelial neoplasms associated with human papillomavirus infection was described. Eyster M, et al: Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. Weber R, et al: Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study. Bessesen M, et al: Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Benhamou Y, et al: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Bodsworth N, et al: the effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. Lin W, et al: Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Birkus G, et al: Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Schlichting P, et al: Clinical relevance of restrictive morphological criteria for the diagnosis of cirrhosis in liver biopsies. Gomez-Dominguez E, et al: Transient elastography: a valid alternative to biopsy in patients with chronic liver disease. Forns X, et al: Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Macias J, et al: Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Sanvisens A, et al: Hyaluronic acid, transforming growth factorbeta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection. Ziol M, et al: Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Tural C, et al: Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus. Macias J, et al: Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term. Shim M, et al: Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination. Ida S, et al: Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. Lazizi Y, et al: Reappearance of hepatitis B virus in immune patients infected with the human immunodeficiency virus type 1. Nunez M, Soriano V: Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Bedimo R, et al: Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. Macias J, et al: Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. Drobeniuc J, et al: Hepatitis E virus antibody prevalence among persons who work with swine. Kamar N, et al: Factors associated with chronic hepatitis in patients with hepatitis e virus infection who have received solid organ transplants. Kamar N, et al: Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. Lawee D: Mild infectious mononucleosis presenting with transient mixed liver disease: case report with a literature review. Shibuya K, et al: Histopathology of cryptococcosis and other fungal infections in patients with acquired immunodeficiency syndrome. Pol S, et al: Microsporidia infection in patients with the human immunodeficiency virus and unexplained cholangitis. Vernon G, et al: Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Ingiliz P, et al: Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Iwasaki M, et al: Noninvasive evaluation of graft steatosis in living donor liver transplantation. Bedogni G, et al: the Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. Rodriguez-Novoa S, et al: Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. Rotger M, et al: Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. Puoti M, et al: Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. Brinkman K, et al: Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. Montessori V, et al: Hepatotoxicity of nucleoside reverse transcriptase inhibitors. Okuda M, et al: Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Moriya K, et al: Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Barbaro G, et al: Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. Maida I, et al: Antiretroviral-associated portal hypertension: a new clinical condition Orenstein R, Tsogas N: Looking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection. Tostmann A, et al: Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. Padmapriyadarsini C, et al: Hepatitis B or hepatitis C co-infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function. Dal Maso L, Franceschi S: Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Monti G, et al: Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Agmon-Levin N, et al: Primary hepatic lymphoma: a case report and review of the literature. Liver involvement in nonhepatotropic viral infections can range from mild derangement of liver biochemistry to fulminant liver failure. In most of these infections, liver inflammation is thought to be a consequence of an immune response to viral antigens rather than a direct hepatic infection. In this article we review liver diseases associated with opportunistic viral infections in immunocompromised hosts, common systemic viral infections, and viral hemorrhagic fevers. Gastrointestinal manifestations such as abdominal pain, nausea, and diarrhea are mild.

A far more common occurrence is bile duct injury after biliary tract or gastric surgery prostate cancer 47 rogaine 5 60 ml buy free shipping. Bile duct injury after laparoscopic cholecystectomy is an increasingly common problem and frequently goes unrecognized during the cholecystectomy mens health quick adjust resistance band discount rogaine 5 online amex. Diagnosis is made by magnetic resonance cholangiopancreatography prostate health supplement order rogaine 5 australia, endoscopic retrograde cholangiopancreatography mens health week 2014 buy 60 ml rogaine 5 visa, or transhepatic cholangiography (see Chapter 10) prostate cancer 7 out of 10 buy rogaine 5 without prescription. Postoperative pancreatitis may also cause bile duct obstruction because of edema in the head of the pancreas. The diagnosis is made by the finding of an elevated serum level of amylase and through a computed tomography scan of the abdomen showing edema of the pancreas and bile duct dilatation. Acute cholecystitis (calculous or acalculous) may occur postoperatively and can be associated with abnormal liver test results and jaundice. Abnormal liver test results are found days to weeks after the institution of therapy. Use of enteral feeding has reduced the incidence of cholestasis in children requiring nutritional support. Postoperative cholecystitis is associated with abdominal pain and fever, which are unusual features of the other types of injury; abdominal ultrasonography should be performed in this situation. Tests for acute hepatitis B and hepatitis C are not usually necessary because they rarely cause posttransfusion hepatitis. EvaluationofPatientsWith PostoperativeLiverDysfunction If the patient is within the first 2 weeks of surgery and has a hepatitis-like injury, anesthetic-related hepatitis or ischemic hepatitis is of major concern (Table 57-2). The development of cholestasis in the immediate postoperative period in a patient who has undergone biliary or gastric surgery suggests bile duct injury. If the patient has undergone major cardiac or abdominal surgery and is infected or has received multiple blood transfusions, benign postoperative cholestasis should be the initial diagnosis. Powell-Jackson P, Greenway B, Williams R: Adverse effects of exploratory laparotomy in patients with unsuspected liver disease. Jan A, Narwaria M, Mahawar K: A systemic review of bariatric surgery in patients with liver cirrhosis. Sleeman D, Namias N, Levi D, et al: Laparoscopic cholecystectomy in cirrhotic patients. Curro G, Baccarani U, Adani G, et al: Laparoscopic cholecystectomy in patients with mild cirrhosis and symptomatic cholelithiasis. Mansour A, Watson W, Shayani V, et al: Abdominal operations in patients with cirrhosis: still a major surgical challenge. Keswani A, Verma A, Dann K, et al: Transcatheter aortic valve implantation in surgically repaired double outlet right ventricle. Bollati M, Moretti C, Omede P, et al: Percutaneous aortic valve replacement in two cases at high surgical risk: procedural details and implications for patient selection. Sharma P, Ananthanarayanan C, Malhortra A, et al: Hyperbilirubinemia after cardiac surgery: An observational study. Boekhorst T, Urlus M, Doesburg W, et al: Etiologic factors of jaundice in severely ill patients. A retrospective study in patients admitted to intensive care unit with severe trauma or with septic intraabdominal complications following surgery and without evidence of bile duct obstruction. Investigation of these inborn errors has provided important information regarding its metabolic pathways. Definitive treatment of some of these disorders continues to be a therapeutic challenge and an impetus for further research. Although bilirubin has interested physiologists mainly as a toxic metabolic product, as an antioxidant it may serve as a defense mechanism against oxidative damage. Jaundice as an Indicator of Hepatic Dysfunction Jaundice and hyperbilirubinemia are frequently used as indicators of liver dysfunction. In contrast, in other hepatocellular diseases such as alcoholic or drug-induced hepatitis, and alcoholic or nonalcoholic liver cirrhosis, jaundice has a dismal prognosis. In the intensive care unit, in septic or multitrauma patients, jaundice is associated with a high mortality rate. In primary biliary cirrhosis, jaundice is a major indicator of poor prognosis, and serial serum bilirubin measurement is one of the tests used for determining the appropriate timing of liver transplant. Impairment of bile flow caused by obstruction of the intrahepatic or extrahepatic biliary tract leads to jaundice. Because this is a postconjugation event, predominantly conjugated bilirubin accumulates in the blood. After relief of bile duct obstruction, jaundice usually resolves within 1 week, although elevated plasma bilirubin levels may linger because of the covalent binding of conjugated bilirubin to albumin. Acquired causes of hyperbilirubinemia, which include hemolysis, liver disease, and biliary obstruction, need to be differentiated from inborn errors of bilirubin metabolism. Although jaundice is a common symptom, its clinical significance varies according to the underlying disease. In some cases a simple bilirubin level determination has more clinical predictive power than a battery of expensive diagnostic tests, including invasive techniques. Therefore sound knowledge of the pathophysiology of bilirubin metabolism is required for interpretation of this simple and valuable liver function test. Introduction Bilirubin is the degradation product of heme, and the bulk of bilirubin is derived from hemoglobin of senescent erythrocytes and hepatic hemoproteins. Bilirubin is potentially toxic but is normally rendered harmless by binding to plasma albumin, conjugation with glucuronic acid, and efficient hepatic clearance. In some disease states, severe unconjugated hyperbilirubinemia can result in encephalopathy (kernicterus). Perhaps because of its distinctive color, bilirubin has attracted the attention of physicians since antiquity. Hippocrates considered it one of the four important humors of the body: blood, phlegm, black bile, and yellow bile. During the last 3 centuries, the chemistry, metabolism, and disposal of bilirubin have been investigated meticulously by generations of chemists, biologists, and clinical investigators. Excretion of bilirubin by the liver has also been studied as a model for hepatic disposal of other biologically important organic anions of limited aqueous solubility. Several 898 Formation of Bilirubin Breakdown of heme results in the daily production of 250 mg to 400 mg of bilirubin in humans. After radiolabeled heme precursors glycine and -aminolevulinic acid are injected into humans or rats, radioactivity is incorporated into bile pigments in two phases. This slower phase is enhanced in conditions associated with ineffective erythropoiesis, such as congenital dyserythropoietic anemias, megaloblastic anemias, iron-deficiency anemia, lead poisoning, and erythropoietic porphyria. When the erythrocyte life span is reduced, as in hemolytic syndromes or intravascular or extravascular hemolysis, the late-labeled peak appears earlier. A prerequisite for this antioxidant action is that toxic ferrous iron that is released on cleavage of the porphyrin ring is efficiently scavenged by ferritin. Whether this protective effect of bilirubin also holds for patients with Gilbert syndrome is unclear. Potential Beneficial Effects of Products of Heme Breakdown Both biliverdin and bilirubin are strong antioxidants, which may be particularly important in the newborn period, when the levels of other natural antioxidants are low. Biliverdin appears to attenuate graft rejection in both cardiac and small intestine transplant models. The evolutionary development and conservation of the energetically expensive mechanisms of bilirubin production and elimination suggest a physiologic benefit for bilirubin. In a large cohort of insurance applicants, the relative mortality rate was higher in individuals who had serum bilirubin levels lower than those in the middle 50% of the population. This observation is consistent with another large study showing an inverse relationship between serum bilirubin levels and cancer mortality in a Belgian population. For example, cell surface biliverdin reductase has been implicated in biliverdin-induced antiinflammatory effects via phosphatidylinositol 3-kinase and Akt signaling. Being less polar, bilirubin crosses placental membranes more readily than does biliverdin,17,18 although some placentate animals, such as nutria and rabbits, excrete biliverdin as the main bile pigment. Measurement of Bilirubin Production At the steady state, bilirubin production equals the synthesis and breakdown of hemoproteins. Normally, bilirubin is almost quantitatively excreted in bile; therefore one can measure bilirubin production by determining its biliary excretion in bile duct­ cannulated experimental animals. Although bilirubin is excreted in bile predominantly as glucuronides, a small fraction is excreted as unconjugated bilirubin, which may undergo enterohepatic cycling. This may become important in patients with terminal ileum dysfunction, such as in Crohn disease, where unabsorbed bile acids may spill over into the cecum, solubilizing the unconjugated bilirubin formed by bacterial deconjugation of bilirubin glucuronides and thereby increasing bilirubin reabsorption. At steady-state levels of plasma bilirubin, the bilirubin removal rate equals the rate of its synthesis. This method does not take into account a small portion of bilirubin that is produced in the liver and excreted directly into bile without appearing in the circulation and therefore slightly underestimates bilirubin production. The oxygen attached to the outer pyrrolenone ring is in a lactam rather than a lactim configuration. X-ray diffraction studies of crystalline bilirubin confirmed hydrogen bonding between each propionic acid side chain and the pyrrolic and lactam sites in the opposite half of the molecule. The integrity of the hydrogen-bonded structure requires the interpyrrolic bridges at positions 4 and 15 of bilirubin to be in trans or Z configuration. Thecarbonbridgesconnecting pyrrolenone rings A and B (C-4) and rings C and D (C-15) are in the Z (trans) configuration. In the liver, conjugation of the propionic acid carboxyls of bilirubin with glucuronic acid moieties disrupts the hydrogen bonds, resulting in the formation of water-soluble conjugates that are readily excreted in bile. Resonance Raman spectroscopic studies of bilirubin-sphingomyelin complexes suggest that the intramolecular hydrogen bonds are disrupted in such complexes, and the propionic acid carboxyls form ion pairs with the quaternary ammonium ion of the choline moiety of sphingomyelin. Therefore reduction of human serum albumin­bound biliverdin to bilirubin results in a conformational inversion from minus to plus helicity. Bilirubin neurotoxicity is caused by the non­protein-bound fraction of unconjugated bilirubin that can diffuse across cell membranes. Moderately increased intracellular bilirubin levels affect astrocytes and neurons, causing mitochondrial damage, which impairs energy metabolism and may induce apoptosis. Binding to cytosolic proteins lowers the intracellular free bilirubin concentration, thereby reducing the toxicity of bilirubin. Because bilirubin cytotoxicity is modified by multiple pathophysiologic factors, the incidence and extent of bilirubin encephalopathy cannot be predicted simply on the basis of plasma bilirubin and albumin concentrations. Bilirubin Encephalopathy in Gunn Rats Bilirubin deposition in specific areas of the brain accompanied by structural damage is termed kernicterus. The Gunn rat is the only spontaneous mutant animal model in which bilirubin-induced brain damage has been observed. Displacement of bilirubin from albumin binding sites by drugs such as salicylates or sulfonamides increases bilirubin accumulation in the brain and may precipitate kernicterus. Therefore for clinical purposes, it is important to calculate the molar ratio between plasma albumin and bilirubin. However, the plasma free bilirubin level does not correlate well with brain bilirubin concentration,58 and it is not certain whether unbound bilirubin is the only toxic species of the pigment. Various degrees of hearing deficiency due to abnormalities of the cochlear nuclei occur commonly as a complication of neonatal hyperbilirubinemia. Brainstem auditory evoked potential studies in Gunn rats indicate functional abnormalities of the central auditory pathways at and rostral to the cochlear nuclei beginning at 17 days of age. Sulfonamides displace bilirubin from albumin binding, thereby promoting the net transfer of bilirubin into neural tissues. Administration of sulfonamides results in reversible abnormalities of brainstem auditory evoked potentials in Gunn rats. A large number of Purkinje cells are affected in the cerebellum of Gunn rats at the age of 7 days; most of these cells degenerate and disappear between day 12 and day 30, resulting in cerebellar hypoplasia. However, synapse formation among these Purkinje cells or with other neural cells may remain abnormal. Photooxidation and Degradation In the presence of light and oxygen, bilirubin undergoes a selfsensitized reaction involving singlet oxygen, resulting in the formation of colorless fragments, chiefly maleimides and propentdyopent adducts. Bilirubin Toxicity the cerebral toxicity of bilirubin in neonatal jaundice has been known for at least 5 centuries. Degeneration of brain tissues associated with yellow pigmentation was reported in 1949. Bilirubin encephalopathy may present with a broad spectrum of neurologic features. In the severest cases, overt kernicterus presents between the third and sixth days of life. The normal Moro reflex is lost, the muscles become hypotonic, the cry is high-pitched, athetoid movements appear, and reflex opisthotonos occurs in response to a startling stimulus. Occasionally, in some children with Crigler-Najjar syndrome type 1, bilirubin encephalopathy may present late with cerebellar symptoms as the presenting feature. Cells of the auditory system that receive synaptic input from end-bulbs or calyces appear to be early targets. The sensitivity of auditory evoked potential testing can be increased by the recording of binaural difference waves obtained by subtraction of the sum of two monaural brainstem auditory evoked potentials from a binaural brainstem auditory evoked potential. Clinical manifestations precede histologic evidence of brain damage by approximately 72 hours. Nonspecific signs of encephalopathy in the neonate may result from other causes, such as cerebral hemorrhage,70 and therefore kernicterus cannot always be diagnosed without pathologic documentation. Conversely, focal bilirubin staining of the brain may occur in other forms of brain injury. Thus, in the absence of neuronal degeneration, bilirubin staining alone does not establish the diagnosis of classic kernicterus. The prognostic significance of a moderate degree of hyperbilirubinemia is not entirely clear.

Discount rogaine 5 60 ml fast delivery. Ideal Weight Calculator for men and women.

For some drugs androgen hormone foods order rogaine 5 60 ml without prescription, changes compatible with diffuse fatty change (Table 56-3) prostate cancer quiz 60 ml rogaine 5 order fast delivery, Mallory-Denk bodies (Table 56-4) androgen hormone network buy rogaine 5 without a prescription, or phospholipidosis (Table 56-5) may be present prostate cancer screening guidelines quality rogaine 5 60 ml. Of particular importance prostate 80 grams rogaine 5 60 ml otc, especially when patients are jaundiced, is the lack of evidence of dilatation of the biliary tree or cholecystitis. Of course, preexisting gallstones may be present, making it somewhat more difficult to arrive at a correct diagnosis. Some drugs, such as acetaminophen, can also cause acute pancreatic, myocardial, or renal injury. If pancreatitis occurs, the pancreas on imaging studies generally shows diffuse enlargement or edema. The major considerations for the differential diagnosis of acute hepatocellular injury attributable to drugs include acute ischemic liver injury; acute viral hepatitis, which may be due to any of the agents that are capable of causing this syndrome; acute congestive hepatitis, including Budd-Chiari syndrome; autoimmune hepatitis; or hepatic decompensation caused by Wilson disease. When liver biopsy is performed on patients with acute hepatocellular injury caused by drugs, typical findings are variable and highly dependent on the offending agent. Other common findings include variable inflammation of the portal tracts, often with a considerable number of polymorphonuclear or eosinophilic forms. Usually this is primarily in zone 3 but it is certainly not restricted to this zone. In most instances of hepatocellular injury, particularly when it has been sudden and acute in onset, there is a rapid resolution of symptoms and signs and improvement of laboratory features when use of the offending agent is discontinued. This does not always occur, however, and in rare individuals drugs appear to be capable of triggering the development of self-perpetuating autoimmune hepatitis. In contrast, the case fatality rate for acetaminophen-induced fulminant hepatic failure is much lower, with only approximately 25% of patients dying and/or requiring liver transplant. It is clear that acute acetaminophen overdose should be treated immediately with N-acetylcysteine. For adults who ingested acetaminophen less than 24 hours before presentation, an N-acetylcysteine loading dose of 140 mg/kg body weight should be given, followed by 70 mg/kg every 4 hours for 17 doses, starting 4 hours after the loading dose. Particularly when hepatocellular-type injury is severe, and/or when it is accompanied by evidence of immunoallergic features, a corticosteroid, such as prednisolone (20-30 mg/day), and azathioprine (1-2 mg/kg body weight per day) are often administered as well. Cholestatic Pattern of Injury the typical presentation of cholestatic hepatitis attributable to drugs is jaundice and pruritus. Nausea, anorexia, or vomiting typically occurs only when the reaction is very severe. A notable exception is the injury due to body-building agents, which typically presents with R > 5 but with a protracted course characterized by later decreases in R, prolonged itching, and jaundice. The liver is usually normal or nearly normal, and there is nothing to suggest chronic liver disease or cholecystitis (see Table 56-2). There are also overlap syndromes of autoimmune cholangitis and autoimmune hepatitis. Bile lakes or other features of extrahepatic obstruction are absent, and as a rule there are no findings of acute cholangitis or pericholangitis, such as one would expect to see in bacterial ascending cholangitis. It is not uncommon for worsening of signs and laboratory features to continue after use of the offending drug has been discontinued, sometimes for as long as 30 to 180 days. There is gradual improvement thereafter, unless the offending agent is readministered or another like it is administered. There are rare instances in which the disease does not resolve but instead evolves to produce the adult vanishing bile duct syndrome, sometimes with progression to secondary biliary cirrhosis. We recommend that ursodeoxycholic acid be given at a dosage of 15 mg/ kg per day to 20 mg/kg per day in two divided doses. If pruritus is severe, the usual treatment is cholestyramine; however, this must be given at times other than when ursodeoxycholic acid or other drugs are administered, because it will bind the drugs and prevent their absorption. Other helpful measures to control pruritus include plasmapheresis and administration of phenobarbital, rifampicin, or naltrexone, although all of these drugs, especially rifampicin, may also cause hepatotoxicity on their own. Mixed Pattern of Injury this pattern, as the name implies, involves features of both hepatocellular and cholestatic injury (see Table 56-2). The typical clinical presentation is nausea, anorexia, and vomiting when it is severe. The considerations for differential diagnosis must include ischemic hepatitis, acute congestive hepatitis, acute viral hepatitis, autoimmune hepatitis, or overlap syndromes of autoimmune cholangitis and hepatitis; hepatic decompensation caused by Wilson disease, primary biliary cirrhosis, primary sclerosing cholangitis, and biliary obstruction attributable to gallstones, tumors, strictures, or primary pancreatic diseases should also be included in the differential diagnosis. The typical treatments are the same as those already described for hepatocellular and cholestatic injuries. Steatotic (Fatty Liver) Pattern of Injury As shown in Table 56-3, there are two major types of fatty accumulation in the liver: microvesicular steatosis results in changes in pure small-droplet fat particles, whereas macrovesicular steatosis is associated with alterations in fewer large-droplet fat molecules. Typically, however, macrovesicular steatosis is present with at least a mild degree of microvesicular steatosis. Patients with these defects commonly present with nausea, anorexia, vomiting, confusion, or coma, the latter attributable to hepatic encephalopathy with prominent and severe hyperammonemia. They often have significant lactic acidosis because of the critical defect in mitochondrial respiration and oxidative phosphorylation. Typical hepatobiliary-pancreatic imaging studies in patients with microvesicular steatosis show a normal liver, pancreas, and spleen, as well as the absence of biliary dilatation or any imaging findings to suggest portal hypertension or chronic liver disease. To clearly visualize the lipid, it may be necessary to perform oil red O staining on frozen sections. This is because there is diffuse lipid accumulation in very small droplets, often smaller than the limit of resolution of light microscopy. There is no displacement of hepatocytic nuclei, such that the lipid may not be apparent in formalin-fixed tissue stained in the routine way. There is minimal inflammation, although apoptotic bodies and evidence of hepatocytic dropout may be present, and there is usually no fibrosis. The usual course is one of rapid improvement if use of the inciting agent is discontinued. However, some patients have such severe defects that they may be unable to recover unless they receive urgent liver transplant. Certainly, all such patients who might be transplant candidates and who develop higher grades of hepatic encephalopathy should rapidly be transferred to a transplant center. If patients can be nursed successfully through the acute phase of the disease, complete recovery with no progression to chronic liver disease will ensue. Noteworthy are two newly approved drugs, mipomersen and lomitapide, for the management of familial hypercholesterolemia. Potential causes of fatty liver are manifold and are discussed in greater detail in Chapters 25 and 26. Drugs and chemicals are among the important causes of fatty liver (see Table 56-3). Most people with fatty liver attributable to alcohol or other conditions that produce macrovesicular steatosis are asymptomatic. When the fatty deposition is severe, hepatomegaly ensues, and patients may have upper abdominal discomfort and a sense of heaviness. It is rare for more severe symptoms, such as nausea, anorexia, vomiting, or jaundice, to occur. The findings of laboratory studies may be entirely normal or may show mild increases in the levels of serum aminotransferases. Typical findings on hepatobiliarypancreatic imaging are diffuse, generalized hepatomegaly. There is generally no biliary dilatation and the pancreas appears normal, or may show increased echogenicity indicative of a fatty deposition in the pancreas. In addition to heavy alcohol use, macrovesicular steatosis is commonly caused by liver disease associated with metabolic syndrome (nonalcoholic fatty liver and nonalcoholic steatohepatitis; see Chapter 26). The typical findings on liver biopsy in patients with drug-induced macrovesicular steatosis are indistinguishable from those caused by alcohol or by nonalcoholic fatty liver. It is common for patients to have these changes because of an element of alcohol and nonalcoholic fatty liver plus use of one or more drugs. Mallory-Denk bodies may develop as a result of alcoholic or nonalcoholic steatohepatitis, and have been associated with several drugs (see Table 56-4). Drug-Induced Liver Injury Due To Specific Agents Anesthetics Of the agents currently used to induce and maintain anesthesia, only the halogenated volatile agents have clinically significant hepatotoxicity. Beginning with halothane in the 1950s, the halogenated anesthetics replaced the routinely used ether and chloroform. Halothane, besides being nonflammable, had much better pharmacokinetics than ether, and had fewer respiratory and cardiac side effects than chloroform. However, postoperative liver injury was soon recognized, especially in patients reexposed to halothane,142,152,153 and it was also an occupational hazard for those administering the anesthetic. However, all have been reported to cause liver injury,155-160 including sevoflurane, which is considered the safest among the newer halogenated agents. Studies of pathogenesis support an immune mechanism for liver injury,146,163 with identification of halothane metabolite­ modified neoantigens in injured livers164 and IgG antibodies to neoantigens in sera of patients. The clinical features of halogenated anesthetic­induced liver injury were reviewed years ago142,152,154 and more recently. Nonspecific symptoms, including fever and malaise, occur days to weeks postoperatively and are followed by marked elevations of aminotransferase levels and then jaundice. Onset is variable, with jaundice occasionally taking more than 1 month to develop. The usual histologic pattern of liver injury is centrilobular necrosis170; however, cholestatic features can also occur. A small percentage of patients develop fatal fulminant liver failure, with some rescued by transplant. However, complete resolution without residual liver dysfunction occurs in most cases. Patients who have survived such reactions should not be reexposed to any halogenated anesthetics. Among parenterally administered agents, both propofol and ketamine are safe and have been extensively used for short procedures. However, cases of clinically significant asymptomatic and if the drug is essential for other reasons, such as methotrexate for the management of rheumatoid arthritis or psoriasis, the decision may be made to continue use of the drug with careful monitoring. In addition to the histopathologic features already described, drugs can cause the accumulation of phospholipids in hepatocytes and other cells (see Table 56-5), vascular lesions in the liver (including peliosis hepatis) (Table 56-6), sinusoidal obstruction or veno-occlusive disease, and arterial vascular compromise, which is manifested as a syndrome that resembles sclerosing cholangitis. By far the most important example of the former is that induced by acetaminophen, which, by mechanisms already described, will produce liver injury in virtually everyone who takes a sufficient dose. Such reactions are called idiosyncratic reactions and are further subdivided according to the accompanying presence or absence of immunoallergic manifestations. Such manifestations include symptoms such as fever, peripheral eosinophilia, rash, arthralgia, and arthritis. Because such neoantigens are displayed on hepatocytes, where most drug metabolism occurs, the net effect may resemble autoimmune hepatitis. In several cases (amoxicillin­clavulanic acid, carbamazepine, flucloxacillin) the causative drugs result in immunoallergic disease, whereas in others (isoniazid, ximelagatran) they do not. Th2phenotypes Womenmoresusceptiblethanmen(as formostautoimmunediseases) Hepatocellular,acute Lessoften,cholestaticormixed Veryrapidrecurrence(1-3doses) Amoxicillin­clavulanicacid -Methyldopa Diclofenac Doxycycline Fenofibrate Halothane Hydralazines Minocycline Nitrofurantoin Penicillins Phenylbutazone Phenytoin Quinidine Statins(veryrarely) Brief(1-5wk). Anticonvulsants Many anticonvulsants have potential hepatotoxic effects (Table 56-9), including traditional agents that have been in use for decades. For example, addition of valproate increases the serum concentration of lamotrigine, with its potential to be toxic, whereas exposure to estrogen-containing contraceptives decrease the concentration of lamotrigine. Phenytoin has been known for decades to cause hepatotoxicity in association with hypersensitivity reactions. These changes are part of hepatic adaptation and generally do not require cessation of therapy. The incidence of this idiosyncratic non­dose-related hepatotoxicity is estimated to be less than 1 in 10,000, and 56% of phenytoin hypersensitivity is associated with some hepatotoxicity. Adverse events in other organ systems can include interstitial nephritis, myositis and rhabdomyolysis, pneumonitis, and marrow suppression. The therapy is discontinuation of use of the drug, which in most cases leads to resolution of toxicity. However, once liver failure develops, the case fatality ratio can be as high as 40%. A phosphate ester prodrug of phenytoin, fosphenytoin, developed for parenteral administration186 should also be avoided. A Swedish analysis187 estimated the risk to be approximately 1 in 6000, which is greater than with phenytoin. Carbamazepine is more likely than phenytoin to cause a pure cholestatic pattern of hepatotoxicity, which occurs in 30% of reactions. Because the injury is immune mediated, rechallenge is not recommended, and both phenytoin and oxcarbazepine should be avoided. Survival after transplant is generally poorer with antiepileptic drugs than other drugs. People with Alpers-Huttenlocher syndrome are at especially high risk, and this is related to mutations in the mitochondrial polymerase gamma gene. If fever, nausea, vomiting, and abdominal pain accompany laboratory evidence of developing hepatic failure and poor seizure control, then liver failure will probably become irreversible. The characteristic histopathologic feature of valproate hepatotoxicity is that of microvesicular steatosis, similar to Reye syndrome, seen mainly in zones 2 and 3. In one report, 61% of patients receiving long-term valproate therapy had sonographic evidence of fatty liver,200 with most having normal concentrations of serum aminotransferases. Valproate therapy has also been reported to decrease serum albumin concentrations by up to 30% without apparent toxicity in a small study of children with severe neurologic disabilities. However, during its first year of use an incidence of hepatic failure of 1 in 6000 (and an aplastic anemia incidence of 1 in 3000) prompted restriction of its use to severe epilepsy not responding to other agents. The paucity of reported cases makes it difficult to describe the clinical characteristics and histopathologic features of felbamate hepatotoxicity. However, presentation occurs between 3 weeks and 6 months of initiation of therapy, with a possible female preponderance. However, there is only one case report of acute liver injury that recurred with reexposure in the literature. Lamotrigine is a chlorinated phenyltriazine anticonvulsant that has been in use for more than 1 decade.

A bruit may be heard in the left upper quadrant in the presence of a splenic arteriovenous fistula prostate zone anatomy order rogaine 5 discount, causing portal hypertension androgen hormone yam purchase generic rogaine 5. Laboratory abnormalities also point to portal hypertension as the potential cause for bleeding if there is thrombocytopenia prostate cancer 2015 order cheap rogaine 5 on line, hypoalbuminemia prostate oncology quizzes rogaine 5 60 ml low price, elevation in the bilirubin prostate 20 buy rogaine 5 with amex, or prolongation in the prothrombin time. Abdominal imaging can confirm splenomegaly, the abnormal configuration of the liver suggesting cirrhosis, obstruction of the extrahepatic portal venous system, and the presence of venous collaterals. When a patient has gastrointestinal bleeding and portal hypertension is suspected to be the cause, the initial step is to establish the location, severity, and the nature of the hemorrhage. It is important to remember that an upper gastrointestinal source of bleeding should be considered, even in the presence of hematochezia because, with brisk bleeding, intestinal transit is so rapid that blood may not be altered in the intestines. The most accurate method of diagnosing bleeding gastroesophageal varices and excluding other lesions is upper endoscopy. It is not currently used in the control of variceal bleeding because of serious systemic side effects. These include negative inotropic and chronotropic effects on the myocardium, leading to reduced cardiac output and bradycardia, as well as systemic vasoconstriction, which may result in bowel necrosis. The vasopressin analog that is more commonly used is terlipressin or triglycl-lysine-vasopressin. Terlipressin is a long-acting synthetic vasopressin analog that has fewer cardiovascular side effects compared with vasopressin. Like vasopressin, terlipressin decreases cardiac output and causes splanchnic vasoconstriction, resulting in a decrease in portal blood flow. As a result of the increase in systemic vascular resistance, systemic arterial blood pressure may increase. The reduction in splanchnic blood flow decreases portal pressure by approximately 20%, even with a single dose of terlipressin. The portal pressure drops between 15 and 30 minutes following administration, and the reduction lasts for approximately 4 hours. The overall efficacy of terlipressin in controlling variceal bleeding is approximately 75% to 80%, especially when administered early. Meta-analysis suggests a decrease in mortality compared with a placebo (relative risk 0. Terlipressin is administered in an initial dose of 2 mg intravenously every 4 hours. After bleeding is controlled, it may be administered at a lower dose of 1 mg every 4 hours for up to 5 days. Side effects of terlipressin are similar to those with vasopressin and include myocardial and intestinal ischemia, but are less common. Somatostatin is a 14­amino acid peptide, which works through somatostatin receptors. Because somatostatin has a half-life of less than 3 minutes, longer-acting analogs of somatostatin such as octreotide, lanreotide, and vapreotide have been synthesized. Somatostatin and its analogs decrease portal pressure by inhibiting the glucagon-mediated postprandial increase in portal blood flow. The usual dose of somatostatin is 250 µg as a bolus followed by an infusion of 250 µg/hr for 5 days. Octreotide is given in a bolus of 50 µg followed by an infusion of 25 to 50 µg/hr. The circulating half-life of octreotide is 80 to 120 minutes, but it does not have a prolonged affect in reducing portal pressure. There is no clear evidence that somatostatin and its analogs are superior to placebo in the control of variceal bleeding. Some studies demonstrate that somatostatin or octreotide may be equivalent to sclerotherapy or terlipressin in the control of acute variceal bleeding. A well-conducted study showed the early administration of vapreotide to be associated with better control of variceal bleeding, but without a reduction in the mortality rate. Only nonselective -blockers should be administered because 1-blockade alone decreases only cardiac output, whereas 2-blockade inhibits splanchnic vasodilatation. The result of 2-blockade is decreased portal blood flow, which reduces portal pressure. The nonselective -blockers available are -Adrenergic Blocking Drugs Somatostatin Analogs Treatment Options for Portal Hypertension­Related Bleeding Pharmacologic Treatment Pharmacologic agents are used in the control of acute variceal bleeding, and in the prevention of either the first variceal bleed or rebleeding. These agents are broadly classified into those that decrease splanchnic blood flow and those that may decrease intrahepatic vascular resistance. Vasopressin and its analogs, and somatostatin and its analogs are the agents typically used to decrease splanchnic blood flow as a means of controlling acute variceal bleeding. There are several agents that may potentially decrease intrahepatic vascular resistance, such as -adrenergic blocking agents, angiotensin receptor blockers, simvastatin, and nitrates. Other agents may decrease portal pressure by decreasing plasma volume, such as diuretics; or decrease intravariceal pressure by contracting the lower esophageal sphincter, such as metoclopramide, but neither approach is currently recommended in the treatment of variceal bleeding. Timolol needs to be administered four times a day and is not widely used in clinical practice. Nadolol is preferred to propranolol because it is less lipid soluble and is excreted mainly through the kidney. The decreased lipid solubility of nadolol probably results in fewer central side effects, such as depression and nightmares. The goal of treatment has traditionally been to reduce the resting heart rate to between 55 and 60 beats/min, or by 25% from the baseline. The heart rate decrease reflects only blockade of the 1-receptor, whereas the 2-blockade effect of decreasing portal blood flow may be more important in decreasing portal pressure. As long as there are no side effects, the dose of -blockers may be increased every 3 to 5 days until a maximum tolerated dose is reached. The usual starting dose of propranolol is 60 mg once daily as a long-acting preparation, whereas nadolol is started at a dose of 40 mg once a day. The median maximum tolerated dose is approximately 80 mg for both long-acting propranolol and nadolol. Approximately 15% of patients have contraindications to -blocker use, including congestive heart failure, severe bronchial asthma, or severe chronic obstructive pulmonary disease, advanced heart blocks, as well as severe aortic stenosis and peripheral vascular disease. Side effects that limit use of -blockers are mainly fatigue, lightheadedness, nightmares, and erectile dysfunction. The hypotension that the nitrates cause by venodilatation results in reflex splanchnic vasoconstriction, which decreases portal flow and reduces portal pressure. In clinical practice within the United States, it is common for patients to be intolerant of nitrates long-term because of side effects of headaches, dizziness, and hypotension. The only longacting nitrate that has been adequately studied for the prevention of variceal bleeding is isosorbide mononitrate. Nitrates are not used either alone or in combination with a -blocker for primary prophylaxis against variceal bleeding. Carvedilol is a nonselective -blocker which, in addition, has alpha vasodilatory effects by blockade of the -receptor. Blockade of the -receptor decreases intrahepatic vascular resistance, which results in a decrease in portal pressure. A randomized controlled trial demonstrated a possible benefit for carvedilol over endoscopic variceal ligation in the prevention of first variceal bleed. It is possible that carvedilol looked promising because of the unusually high rate of bleeding in the variceal ligation group. Long-term administration of prazosin has been associated with an increased risk of sodium retention and ascites. Neither losartan nor the angiotensin-2 receptor antagonist, irbesartan, have been clinically effective, and may worsen renal function. Simvastatin may decrease intrahepatic resistance while maintaining hepatic blood flow and decreasing portal pressure, and should be the subject of future studies in the prevention of variceal bleeding. However, administration of endothelin antagonists has been associated with a decrease in systemic blood pressure, which could worsen renal function. Thus, at the current time, there are no pharmacologic agents that can be used in clinical practice that decrease portal pressure predominantly by decreasing intrahepatic vascular resistance. Endoscopic Therapy the only modality that can be used for the entire spectrum of primary prevention of variceal bleeding, control of acute variceal bleeding, and prevention of variceal rebleeding is endoscopic therapy. Sclerotherapy Both short-acting nitrates such as nitroglycerin and long-acting nitrates such as isosorbide mononitrate have been used in the treatment of portal hypertension­related bleeding. Even though these agents were thought to decrease intrahepatic resistance, they the sclerotherapy technique involves intravariceal or paravariceal injection of a sclerosing agent, such as sodium tetradecyl sulfate, ethanolamine oleate, or sodium morrhuate. Because of the difficulty in determining whether an injection is intravariceal or paravariceal, most patients probably receive a combination of both paravariceal and intravariceal injections. Repeat injections are carried out at 1- to 4-week intervals until the varices are obliterated. Injection of varices at weekly intervals results in quicker obliteration of the varices, but a higher risk of sclerotherapy ulcers. Side effects of endoscopic sclerotherapy include ulceration with bleeding, strictures, and perforation. Both proton pump inhibitors and sucralfate may decrease the risk of variceal sclerotherapy ulcer-related bleeding. Postsclerotherapy dysphagia is due to a combination of stenosis and esophageal dysmotility. The plastic device that holds the rubber bands is now transparent, which allows better visualization of the varix. Complications of endoscopic variceal ligation are less severe than following sclerotherapy, but include post-banding ulcers, hemorrhage, and esophageal strictures. Endoscopic variceal ligation is the preferred endoscopic therapy of esophageal varices. Cyanoacrylate Glue Injection longer polymerization time than butyl cyanoacrylate due to a longer ester side chain and is, hence, used undiluted. The N-butyl2-cyanoacrylate has to be diluted with Lipiodol to delay polymerization. When injected intravascularly, cyanoacrylates solidify and form a cast of the vessel. A prominent eosinophilic inflammation is seen in animal studies within the first day with tissue necrosis occurring by approximately the seventh day. Glue therapy is used to control acute gastric variceal bleeding from isolated gastric varices or type 2 gastroesophageal varices. There are insufficient data to recommend the use of glue for prophylactic therapy to prevent gastric variceal bleeding. Glue injection is avoided in the presence of known large spontaneous splenorenal shunts because of the concern for risk of pulmonary embolization. With hepatopulmonary syndrome or intracardiac shunts, there is a risk of cerebral embolism. Detachable Snares and Clips Gastric varices may be obliterated by injection of polymers of cyanoacrylate. Food and Drug Administration for cutaneous wound closure, has been used "off label" for obturation of bleeding gastric varices. Detachable snares, available in varying diameters, have typically been used in the treatment of large polyps in the colon. Because detachable snares have "tails," they can interfere with visualization at endoscopy. Furthermore, traction of the varix during detachment of the snare can cause the varix to tear with an increase in bleeding. The data suggest that the snares are technically difficult to apply; thus there is a concern about widespread use. Snares are clearly not superior to endoscopic variceal ligation in the treatment of esophageal varices. There could be a potential role for detachable snares in the treatment of gastric varices, but the safety of this device should be demonstrated before detachable snares can be widely studied. Other than case reports or small series, the experience with this device is very limited and, again, widespread use in the treatment of variceal bleeding is not recommended. The uncovered portion of the stent anchors to the portal vein, whereas the polytetrafluoroethylene-covered portion lines the tract in the hepatic parenchyma. The major advantage of covered stents is that the frequency of shunt stenosis is reduced. Procedure-related mortality is usually 1% to 2% and is related to intraabdominal bleeding or pulmonary edema. The major long-term complications of the procedure include shunt occlusion and hepatic encephalopathy. A portocaval pressure gradient greater than 12 mm Hg indicates shunt stenosis which is treated by angioplasty or with an additional stent. A transfemoral route is used to access the left renal vein and then the gastrorenal shunt. There is limited experience with this procedure and the long-term durability is uncertain. Balloon Tamponade Approximately 10% of patients with an acute variceal bleeding are refractory to pharmacologic and endoscopic treatment. Tamponade by a balloon is possible because the varices are superficial and thin-walled and the flow of blood is via submucosal vessels in the fundus of the stomach to the esophageal varices. Tamponade of either gastric or esophageal varices is appropriate and carried out by inflating a balloon either in the stomach or the esophagus, although inflation of the gastric balloon alone is preferred. The Sengstaken-Blakemore tube is a triple lumen tube, with one tube used for aspirating gastric contents; another leads to a gastric balloon with 200 to 400 mL in volume; and the third leads to an esophageal balloon.

References

• Armstrong RN. Glutathione-S-Transferases. Vol 3.
• Wayne MA: Conversion of paroxysmal atrial tachycardia by facial immersion in ice water. JACEP 5:434-435, 1976.
• Loeb DS, Ribeiro A, Menke DM. Hodgkin's disease of the esophagus: report of a case. Am J Gastroenterol 1999;94:520.
• Nair D, Carrigan TP, Curtin RJ, et al: Association of coronary atherosclerosis detected by multislice computed tomography and traditional risk-factor assessment. Am J Cardiol 2008;102:316-320.
• Fuchs, G.J. Ultrasonic lithotripsy in the ureter. Urol Clin North Am 1988;15:347-359.
• Liao, C.-H., Chueh, S.-C., Lai, M.-K. et al. Laparoscopic adrenalectomy for potentially malignant adrenal tumors greater than 5 centimeters. J Clin Endocrin Metab 2006;91: 3080-3083.